mCRPC patients receiving 225Ac-PSMA-617 therapy in the post-androgen deprivation therapy setting : response to treatment and survival analysis
Loading...
Date
Authors
Sathekge, Mike Machaba
Bruchertseifer, Frank
Vorster, Mariza
Lawal, Ismaheel Opeyemi
Knoesen, Otto
Mahapane, Johncy
Davis, Cindy
Mdlophane, Amanda
Maes, Alex
Mokoala, Kgomotso M.G.
Journal Title
Journal ISSN
Volume Title
Publisher
Society of Nuclear Medicine
Abstract
Please read abstract in the article.
Description
Keywords
225Ac-PSMA-617, Prostate specific membrane antigen (PSMA), Metastatic castration-resistant prostate cancer (mCRPC), Androgen deprivation treatment (ADT), Therapy response, PSA response, Prostate carcinoma, Prostate specific antigen (PSA), SDG-03: Good health and well-being
Sustainable Development Goals
Citation
Sathekge, M., Bruchertseifer, F., Vorster, M., Lawal, I.O., Knoesen, O., Mahapane, J., Davis, C., Mdlophane, A., Maes, A., Mokoala, K., Mathabe, K., Van de Wiele, C. & Morgenstern, A. 2022, 'mCRPC patients receiving 225Ac-PSMA-617 therapy in the post-androgen deprivation therapy setting: response to treatment and survival analysis', Journal of Nuclear Medicine, vol. 63, no. 10, pp. 1496-1502, doi : 10.2967/jnumed.121.263618.